Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.70K | 19.20K | -- | -- | 637.30K |
| Total Other Revenue | 1.58M | 1.63M | 1.81M | 1.82M | 1.05M |
| Total Revenue | 1.60M | 1.65M | 1.81M | 1.82M | 1.69M |
| Cost of Revenue | 10.05M | 10.36M | 8.30M | 8.37M | 7.55M |
| Gross Profit | -8.45M | -8.72M | -6.49M | -6.55M | -5.86M |
| SG&A Expenses | 1.71M | 1.76M | 2.45M | 2.47M | 2.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 52.20K | 53.90K | -69.40K | -70.00K | 32.80K |
| Total Operating Expenses | 11.81M | 12.18M | 10.68M | 10.78M | 9.59M |
| Operating Income | -10.21M | -10.53M | -8.88M | -8.95M | -7.90M |
| Income Before Tax | -9.32M | -9.61M | -8.87M | -8.95M | -3.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.32M | -9.61M | -8.87M | -8.95M | -3.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.32M | -9.61M | -8.87M | -8.95M | -3.46M |
| EBIT | -10.21M | -10.53M | -8.88M | -8.95M | -7.90M |
| EBITDA | -9.72M | -10.02M | -8.68M | -8.76M | -7.49M |
| EPS Basic | -0.07 | -0.07 | -0.09 | -0.09 | -0.03 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.02 |
| EPS Diluted | -0.07 | -0.07 | -0.09 | -0.09 | -0.03 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.02 |
| Average Basic Shares Outstanding | 132.38M | 132.38M | 100.96M | 100.96M | 101.38M |
| Average Diluted Shares Outstanding | 132.38M | 132.38M | 100.96M | 100.96M | 101.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |